Miramar Therapeutics

Miramar Therapeutics is a preclinical-stage biotechnology company dedicated to developing novel small molecule therapies for the treatment of cancer. The company's core technology focuses on the reactivation of mutant p53 proteins, a critical tumor suppressor that is functionally silenced in a majority of human malignancies. Its lead candidate, MIRA-1, is designed to restore the wild-type conformation and transcriptional activity of mutant p53, thereby triggering selective apoptosis in cancer cells. Founded as a spin-out from the University of Michigan, Miramar Therapeutics leverages proprietary chemical scaffolds to target the "undruggable" p53 pathway. While the company's approach addresses a significant unmet need in oncology, it has maintained a low public profile in recent years. The platform holds potential for broad application across various solid tumors, including ovarian and breast cancers.